Dr Kieran Docherty (University of Glasgow, Glasgow, UK) discusses the results of the DAPA-HF trial.
In the DAPA-HF trial, the SGLT2 inhibitor, dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction (HFrEF). Its use was examined to assess if the benefit was consistent in relation to background HF therapy.
Recorded remotely from Glasgow, 2020.
1. What was the rationale behind the analysis?
2. What patients were included and what were your endpoints?
3. What were your findings?
4. How should this study influence practice?
5. What is the study's take-home message for practising clinicians?
Interviewer: Mirjam Boros
Recording Editor: Natascha Wienand